Evidence map›Paper›PMID 41601601›Full record

ArticlePharmacological research. Natural products2025

Dose-dependent evaluation of chronic oleocanthal on metabolic phenotypes and organ toxicity in 5xFAD mice.

Euitaek Yang, Nour F Al-Ghraiybah, Amer E Alkhalifa, Lauren N Woodie, Samuel P Swinford, Judy King, Michael W Greene, Amal Kaddoumi

Abstract read
In one paragraph

Article in Pharmacological research. Natural products, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. A comprehensive review ofRSC advances · 2026
    Review
  3. The Olive PhenolicNutrients · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Euitaek YangDepartment of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University; Auburn, AL 36849, USA.
Nour F Al-GhraiybahDepartment of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University; Auburn, AL 36849, USA.ORCID 0009-0007-7278-9134
Amer E AlkhalifaDepartment of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University; Auburn, AL 36849, USA.
Lauren N WoodieDepartment of Nutritional Sciences, College of Human Sciences, Auburn University; Auburn, AL 36849, USA.ORCID 0000-0003-2427-4586
Samuel P SwinfordDepartment of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University; Auburn, AL 36849, USA.ORCID 0009-0003-1404-1364
Judy KingDepartment of Basic Sciences, DeBusk College of Osteopathic Medicine, Lincoln Memorial University, Knoxville, TN 37932, USA.
Michael W GreeneDepartment of Nutritional Sciences, College of Human Sciences, Auburn University; Auburn, AL 36849, USA.ORCID 0000-0002-6443-8269
Amal KaddoumiDepartment of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University; Auburn, AL 36849, USA.ORCID 0000-0001-9792-7766

Funding

Olive-derived oleocanthal as a novel natural product molecule to restore cerebrovascular function and integrity in a CAA mouse modelR21NS101506 · NINDS · AUBURN UNIVERSITY AT AUBURN · PI KHALIL KADDOUMI, AMAL F, PANIZZI, PETER ROLF · 2017 to 2018
$401k
Evaluation of oral oleocanthal to prevent and/or treat Alzheimer’s disease and related dementiasR43AG061952 · NIA · OLEOLIVE, INC. · PI CARDELLI, JAMES · 2018 to 2019
$337k
NIA NIH HHS R43 AG061952NINDS NIH HHS R21 NS101506
6 · The paper itself

Abstract

In Alzheimer's disease (AD), alterations in the basal metabolic rate (BMR) and energy expenditure, known as metabolic phenotyping, are present early in the disease, which progresses as the disease advances. The Mediterranean diet, including extra-virgin olive oil (EVOO), has been known to reduce AD risk. Oleocanthal (OC) is a major phenolic compound in EVOO. Previous research showed that OC reduced brain amyloid-β, tau hyperphosphorylation, neuroinflammation, and improved blood-brain barrier and memory functions in AD mouse models. In this work, we aimed to investigate the dose-dependent impact of chronic oral OC treatment on modulating metabolic phenotypes affected by AD and its toxicity in 5xFAD mice, an AD mouse model. 5xFAD mice were treated with OC for 3 months, starting at the ages of one (prevention mode, before the pathology hallmarks appear) and 6 months (treatment mode, after the pathology hallmarks appear). Findings demonstrated OC altered metabolic phenotypes in the 5-20 mg/kg dose range in both groups. Furthermore, OC proved not toxic except at 20 mg/kg, where hepatic toxicity is observed. In conclusion, these findings highlight the OC effect in rectifying metabolic phenotypes in AD. However, it limits the dose range in mice to 5 and 10 mg/kg despite exhibiting a favorable response in metabolic parameters due to observed hepatotoxicity with the 20 mg/kg.

Indexed as

5xFADAlzheimer’s diseaseAmyloid-βMetabolic phenotypeOleocanthalPhenotype changesPromethion cages

Identifiers

PMID41601601
PMCPMC12833832

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.